Bayer has entered an exclusive global licensing and collaboration agreement with Kumquat Biosciences to develop and commercialize Kumquat’s investigational KRAS G12D inhibitor. This move targets a prevalent oncogenic variant found in pancreatic, colorectal, and lung cancers that currently lacks effective therapies. With the recent FDA clearance for Kumquat's investigational new drug application, Bayer will lead later-stage development and commercialization efforts. The deal could yield up to $1.3 billion in combined milestone and royalty payments for Kumquat. This partnership positions Bayer prominently in precision oncology by addressing a major unmet need linked to KRAS mutations found in roughly 25% of human cancers.